These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 24798291

  • 1. Structural changes and differentially expressed genes in Pseudomonas aeruginosa exposed to meropenem-ciprofloxacin combination.
    Siqueira VL, Cardoso RF, Caleffi-Ferracioli KR, Scodro RB, Fernandez MA, Fiorini A, Ueda-Nakamura T, Dias-Filho BP, Nakamura CV.
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3957-67. PubMed ID: 24798291
    [Abstract] [Full Text] [Related]

  • 2. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I, Kaynar-Tascioglu J, Kaya B, Goktas P.
    Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
    [Abstract] [Full Text] [Related]

  • 3. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.
    Buyck JM, Tulkens PM, Van Bambeke F.
    Antimicrob Agents Chemother; 2015 Jan; 59(1):258-68. PubMed ID: 25348528
    [Abstract] [Full Text] [Related]

  • 4. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.
    Ermertcan S, Hoşgör M, Tünger O, Coşar G.
    Scand J Infect Dis; 2001 Jan; 33(11):818-21. PubMed ID: 11760161
    [Abstract] [Full Text] [Related]

  • 5. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M, Mataseje LF, Loo V, Walkty A, Adam HJ, Hoban DJ, Zhanel GG, Mulvey MR, Canadian Antimicrobial Resistance Alliance (CARA).
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [Abstract] [Full Text] [Related]

  • 6. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
    Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2646-54. PubMed ID: 20368395
    [Abstract] [Full Text] [Related]

  • 7. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
    Pankuch GA, Lin G, Seifert H, Appelbaum PC.
    Antimicrob Agents Chemother; 2008 Jan; 52(1):333-6. PubMed ID: 17967915
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I, Kucukercan M, Ceran N.
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
    Srivastava P, Sivashanmugam K.
    Infect Genet Evol; 2021 Aug; 92():104824. PubMed ID: 33774177
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA, Blazquez AM, Fresnadillo MJ, Garcia Sanchez E, Garcia Sanchez JE, Trujillano Martin I.
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [Abstract] [Full Text] [Related]

  • 11. In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
    Goodlet KJ, Nicolau DP, Nailor MD.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [Abstract] [Full Text] [Related]

  • 12. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
    Kanellakopoulou K, Sarafis P, Galani I, Giamarellou H, Giamarellos-Bourboulis EJ.
    Int J Antimicrob Agents; 2008 Jul; 32(1):33-9. PubMed ID: 18538547
    [Abstract] [Full Text] [Related]

  • 13. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF, Liu CP, Wang NY, Shih SC.
    BMC Infect Dis; 2016 Aug 24; 16(1):444. PubMed ID: 27553962
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J, Mazucheli J, Barros JPDR, Szczerepa MMDA, Nishiyama SAB, Carrara-Marroni FE, Sy S, Fidler M, Sy SKB, Tognim MCB.
    Antimicrob Agents Chemother; 2019 Jun 24; 63(6):. PubMed ID: 30910903
    [Abstract] [Full Text] [Related]

  • 15. Molecular detection of type III secretory toxins in Pseudomonas aeruginosa isolates.
    Jarjees KK.
    Cell Mol Biol (Noisy-le-grand); 2020 Jul 31; 66(5):9-14. PubMed ID: 33040805
    [Abstract] [Full Text] [Related]

  • 16. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO.
    Int J Antimicrob Agents; 2006 Mar 31; 27(3):224-8. PubMed ID: 16464562
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
    Solak S, Willke A, Ergönül O, Tekeli E.
    Int J Antimicrob Agents; 2005 Feb 31; 25(2):181-2. PubMed ID: 15664492
    [No Abstract] [Full Text] [Related]

  • 18. Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing.
    Holger DJ, Lev KL, Kebriaei R, Morrisette T, Shah R, Alexander J, Lehman SM, Rybak MJ.
    J Appl Microbiol; 2022 Sep 31; 133(3):1636-1649. PubMed ID: 35652690
    [Abstract] [Full Text] [Related]

  • 19. Transcriptional Analysis of MexAB-OprM Efflux Pumps System of Pseudomonas aeruginosa and Its Role in Carbapenem Resistance in a Tertiary Referral Hospital in India.
    Choudhury D, Das Talukdar A, Dutta Choudhury M, Maurya AP, Paul D, Dhar Chanda D, Chakravorty A, Bhattacharjee A.
    PLoS One; 2015 Sep 31; 10(7):e0133842. PubMed ID: 26221722
    [Abstract] [Full Text] [Related]

  • 20. Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance.
    Rizek C, Fu L, Dos Santos LC, Leite G, Ramos J, Rossi F, Guimaraes T, Levin AS, Costa SF.
    Ann Clin Microbiol Antimicrob; 2014 Sep 02; 13():43. PubMed ID: 25179208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.